{"id":"e8a28bb9-2cb8-5759-a670-aa340fd387bf","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:clinical-cyp2c19","predicate":"decreases_in_recorded_experiment","statement":"Increased omeprazole exposure after modafinil supports CYP2C19 inhibition; Table 4 ratios were 1.36 and 1.85 after single and repeated dosing.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"6138c647-f2c0-54f4-836d-2f5c1dbefb4a","mechanism_event_label":"Increased omeprazole exposure after modafinil supports CYP2C19 inhibition; Table 4 ratios were 1.36 and 1.85 after single and repeated dosing.","subject":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"object":{"id":"cc080b54-fd5d-5cc0-930e-2cb86c116c68","slug":"cyp2c19","display_name":"Human cytochrome P450 2C19","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"6138c647-f2c0-54f4-836d-2f5c1dbefb4a","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:clinical-cyp2c19-event","event_type":"biochemical_relationship","label":"Increased omeprazole exposure after modafinil supports CYP2C19 inhibition; Table 4 ratios were 1.36 and 1.85 after single and repeated dosing.","description":"These support time-dependent CYP3A induction and CYP2C19 inhibition. The abstract's estimates differ slightly; the draft's approximately 34%/90% changes follow the abstract. **Source discrepancy:** the discussion calls the dextromethorphan interval 0.69–0.88 contained within 0.85–1.20. That statement is mathematically false. Retain the measurement and query the analysis; do not promote it directly to proven CYP2D6 induction or a definite null. [Trial, Table 4 and discussion](https://pmc.ncbi.nlm.nih.gov/articles/PMC5809348/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"role":"tested factor","stoichiometry":null,"state_label":"Single/repeated modafinil","sequence_order":0,"notes":""},{"entity":{"id":"cc080b54-fd5d-5cc0-930e-2cb86c116c68","slug":"cyp2c19","display_name":"Human cytochrome P450 2C19","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"a9941a82-a3e4-5b0a-9a98-484451d914e0","slug":"omeprazole","display_name":"Omeprazole","entity_type_key":"small_molecule"},"role":"probe drug","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract and PMC methods, Tables 3/4, results and discussion inspected; numerical inconsistency preserved in evidence-notes.json.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Single/repeated modafinil\", \"comparator\": \"Baseline without modafinil\", \"endpoint\": \"Increased omeprazole exposure after modafinil supports CYP2C19 inhibition; Table 4 ratios were 1.36 and 1.85 after single and repeated dosing.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Six-person clinical phenotyping study; abstract differs slightly from full Table 4.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Increased omeprazole exposure after modafinil supports CYP2C19 inhibition; Table 4 ratios were 1.36 and 1.85 after single and repeated dosing.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. | 2018 | DOI 10.1111/bcp.13478 | PMID 29178272 | https://pmc.ncbi.nlm.nih.gov/articles/PMC5809348/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 126-126; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b7ea7a9a-791c-527b-890b-a38b48555710","evidence_kind":"source_excerpt","locator":"Lines 126-126","start_line":126,"end_line":126,"excerpt":"These support time-dependent CYP3A induction and CYP2C19 inhibition. The abstract's estimates differ slightly; the draft's approximately 34%/90% changes follow the abstract. **Source discrepancy:** the discussion calls the dextromethorphan interval 0.69–0.88 contained within 0.85–1.20. That statement is mathematically false. Retain the measurement and query the analysis; do not promote it directly to proven CYP2D6 induction or a definite null. [Trial, Table 4 and discussion](https://pmc.ncbi.nlm.nih.gov/articles/PMC5809348/)","model_system":"Six-person clinical phenotyping study; abstract differs slightly from full Table 4.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"17a64928-eaa2-5117-ba4f-52dcbdf9cc9e","stable_key":"import-6660bba2-4fa0-590a-bf52-9803a24bea9f","title":"Modafinil: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"006008cb4cfd183dd3b0846d3abc66c8ebf40cf1b6bd1f0bcdb4f4d937a8e115","revision_id":"c85b3e2e-c18a-59fc-9e79-5c375e64d119","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}